01 Antibody-Drug Conjugates Are Expanding Targeted Treatment Options The ovarian cancer market analysis shows that advances in biomarker-based drug targeting and the need for more precise therapies are expanding the use of antibody-drug conjugates in ovarian cancer treatment. For example, mirvetuximab soravtansine received FDA approval for FRα-positive, platinum-resistant ovarian cancer, with the MIRASOL trial reporting an overall response rate of 42% compared with 16% for investigator-choice chemotherapy. This development expands targeted treatment options for patients with specific tumor biomarkers and strengthens the role of antibody-drug conjugates in ovarian cancer care.
02 PARP Inhibitors Are Enabling More Selective Patient Segmentation Evidence on biomarker-specific treatment responses and long-term survival outcomes is making PARP inhibitor use more selective across ovarian cancer patient populations. FDA reviews identified potential overall-survival concerns in some biomarker-negative populations, leading to restrictions on several PARP inhibitor indications, particularly toward patients with tumor BRCA mutations. This development increases the importance of BRCA and homologous recombination deficiency (HRD) testing in treatment selection and supports more targeted use of PARP inhibitors in ovarian cancer care.
01 High Recurrence Rates and Biomarker-targeted Therapies Drive Market Growth. High recurrence rates in ovarian cancer create continued demand for therapies used after patients progress following initial treatment.The need for repeated treatment increases utilization of chemotherapy, targeted therapies, and maintenance options across later lines of care.This sustained demand encourages pharmaceutical companies to expand treatment pipelines for recurrent and platinum-resistant disease.For example, bevacizumab is used with chemotherapy in certain patients with recurrent ovarian cancer, supporting demand for combination-based treatment approaches.Greater use of tumor biomarkers helps clinicians identify patients who may benefit from therapies designed for specific molecular characteristics.This approach expands demand for diagnostic testing alongside targeted medicines and creates more defined patient populations for pharmaceutical products.The broader use of biomarker testing also encourages drug developers to investigate additional molecular targets and expand specialized treatment portfolios.For example, FR-α testing helps identify patients who may be eligible for mirvetuximab soravtansine in certain platinum-resistant ovarian cancers
01 High Treatment Costs and Limited Access to Advanced Therapies Restrain Market Expansion. High treatment costs can limit access to surgery, chemotherapy, targeted therapies, and supportive care, especially for patients with limited healthcare coverage. The financial burden can lead to delayed treatment decisions, reduced therapy uptake, or interruptions in long-term treatment. These affordability barriers can restrict patient access and slow the expansion of advanced ovarian cancer therapies.Limited availability of advanced therapies and specialized oncology services can restrict treatment options for eligible ovarian cancer patients. Unequal access to targeted therapies, biomarker testing, and specialized treatment centers can delay the use of newer treatment approaches.These access gaps can reduce adoption of advanced therapies and limit market growth across underserved regions
01 Companion Diagnostics And Patient Support Programs Offers Growth Opportunities. Pharmaceutical companies, diagnostic developers, and oncology providers can use companion diagnostics to support therapy selection and treatment monitoring. Demand for molecular testing can create additional revenue through diagnostic kits, laboratory services, and partnerships between drug and diagnostic companies. Companies such as Roche and Thermo Fisher Scientific operate diagnostic platforms that support this opportunity.Pharmaceutical companies, oncology centers, and specialty healthcare providers can offer treatment navigation, adherence support, financial assistance, and patient education services. These programs can create service-based revenue opportunities while supporting continuity of care during lengthy treatment pathways. Companies such as AstraZeneca and Pfizer operate patient-support initiatives across oncology.
June 2026 NHS England approved mirvetuximab soravtansine (Elahere) for eligible women with FRα-positive advanced platinum-resistant ovarian cancer, making it the first new NHS-funded treatment for this patient population in more than two decades. Clinical studies showed improved progression-free survival and overall survival compared with chemotherapy.
March 2026 The U.S. FDA approved Corcept Therapeutics' relacorilant (Lifyorli) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior systemic treatment regimens, including prior bevacizumab. The approval was supported by the Phase III ROSELLA trial, which demonstrated improved progression-free survival.
February 2026 The U.S. FDA approved Merck's pembrolizumab (Keytruda), including the subcutaneous formulation Keytruda Qlex, in combination with paclitaxel (with or without bevacizumab) for PD-L1-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after one or two prior systemic therapies. The FDA also approved the PD-L1 IHC 22C3 pharmDx companion diagnostic from Agilent Technologies.
December 2025 Researchers developed an artificial intelligence (AI)-based system to assess peritoneal carcinomatosis during diagnostic laparoscopy for advanced ovarian cancer. The technology helps standardize surgical decision-making by automatically estimating tumor burden and surgical resectability.